Oncology

16 June, 2020 The global science-led biopharmaceutical company said the detailed results from both the Phase II ACE-CL-001 trial and the pivotal Phase III ASCEND trial showed the long-term efficacy and tolerability of Calquence (acalabrutinib) in chronic lymphocytic leukaemia (CLL), one of the most common types of adult leukaemia. AstraZeneca presented the results of the […]

01 June, 2020 The clinical stage biopharmaceutical company presented the safety and efficacy results from Part I of the Matins trial in a poster at the virtual ASCO20 (American Society of Clinical Oncology) Annual Meeting. During the ASCO poster presentation, Faron Pharmaceuticals said the ongoing phase I/II Matins clinical trial is investigating the tolerability, safety […]

Gene and cell therapy group Oxford Biomedica has signed a one-year clinical and commercial supply agreement with AstraZeneca for the manufacture of a Covid-19 vaccine candidate. The agreement relates to the GMP manufacture of the adenovirus vector based Covid-19 vaccine candidate, AZD1222, which recently entered clinical trials at multiple sites in the UK. Oxford Biomedica […]

18 May, 2020 The research-driven pharmaceutical company said the new acquisition provides assets targeting the tumour stroma and myeloid cells. Boehringer Ingelheim also announced it is collaborating with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy, a leading cause of blindness. The first programme, now in late preclinical development, is an antibody inhibitor of […]

The Israel based developer of nearly painless intradermal delivery solutions for vaccines and drugs said it is joining forces with leading vaccine and immunotherapy companies worldwide to share its proprietary MicronJet microneedle device. According to NanoPass, the aim is to enable the development of a safe, effective and affordable vaccine to help in the fight […]

The CRISPR revolution arrives in immuno-oncology By Helen Stewart-Miller and Thomas Hope Volume 21 Issue 2 – Spring 2020 CRISPR-cas9 technology is having an exciting impact on drug discovery as a whole, but more specifically CRISPR presents enormous opportunities in targeted screening for immuno-oncology research. Clustered regularly-interspaced short palindromic repeats (CRISPR) were first detected in […]

Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 – Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic diseases and cancer has never been greater. […]

By Dr William Olds and Dr Deepa Shankar While the antibody market has evolved into a multibillion-dollar industry enabling the discovery of cures, disease diagnosis and basic science acceleration, this has allowed low quality antibodies to hit the market. With a large crisis in reproducibility, the need for high quality antibodies has never been greater. […]

ADCs and solid tumours – The payload revolution that drives therapeutic opportunities in unmet need By Dr Jenny Thirlway Volume 21 Issue 2 – Spring 2020 The fight against cancer is ongoing. Despite progress in many indications, mortality rates for some of the most difficult to treat solid tumour types have not improved substantially since […]

Antimicrobial resistance threatens to undermine our healthcare system By Dr Peter Jackson Volume 21 Issue 2 – Spring 2020 The immediate global challenge to human health and our economic stability due to coronavirus acts as a stark reminder that infectious disease preparedness cannot be ignored. While antimicrobial resistance (AMR) does not present the imminent ‘tsunami’ […]